Levinthal Biotech has successfully raised several tens of millions of RMB in a Pre-A financing round to advance its AI-driven protein design platform, Pallatom.

Target Information

Levinthal Biotech, known as "力文所" in Chinese, is a pioneering company in the field of AI-driven protein design, headquartered in Hangzhou, China. Recently, the company successfully secured several tens of millions of RMB in a Pre-A financing round led by Jinyumaowu, with JunKedanmu participating, and Zhoudushi Capital serving as the exclusive financial advisor.

The funding will primarily be directed toward accelerating the technological iteration of its all-atom protein design platform, Pallatom, expanding its commercialization pipeline, and recruiting global talent. Notably, Pallatom has addressed the challenge of designing cyclic peptides with mixed chirality for the first time globally, paving new pathways for the development of next-generation cyclic peptide drugs.

Industry Overview

The protein design industry in China is rapidly evolving, due to significant advancements in artificial intelligence and biotechnology. As the demand for innovative therapeuti